MAM
TXG icon

Meeder Asset Management’s 10x Genomics TXG Stock Holding History

Meeder Asset Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-586
Closed -$21.4K – 820
2022
Q4 		$21.4K Buy
+586
New +$19.2K ﹤0.01% 605
2022
Q3 		– Sell
-80
Closed -$4K – 2382
2022
Q2 		$4K Buy
80
+43
+116% +$2.23K ﹤0.01% 1738
2022
Q1 		$3K Buy
+37
New +$3.24K ﹤0.01% 1978
2021
Q4 		– Sell
-7
Closed -$1K – 2268
2021
Q3 		$1K Sell
7
-3
-30% -$515 ﹤0.01% 2382
2021
Q2 		$2K Hold
10
– – ﹤0.01% 2255
2021
Q1 		$2K Buy
10
+1
+11% +$173 ﹤0.01% 2117
2020
Q4 		$1K Buy
+9
New +$1.31K ﹤0.01% 1748

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

Meeder Asset Management's TXG Position: Q1 2023 in Review

Meeder Asset Management sold out of 10x Genomics (TXG) in Q1 2023, closing a stake of 586 shares — an estimated $21.4K sold.

Meeder Asset Management first reported a position in TXG in Q4 2020 and held it in 7 quarters. The position peaked at $21.4K in Q4 2022. 258 funds tracked by Wall St. Rank hold TXG as of Q1 2023.

  • Meeder Asset Management reported no remaining 10x Genomics position as of Q1 2023 after selling out during the quarter.
  • Meeder Asset Management sold 586 10x Genomics shares in Q1 2023, an estimated $21.4K.
  • Meeder Asset Management first reported a position in 10x Genomics in Q4 2020 and held it in 7 quarters.
  • Meeder Asset Management's 10x Genomics position peaked at $21.4K in Q4 2022.
  • 258 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2023.

Based on Meeder Asset Management's 13F filing for Q1 2023, filed 15 May 2023.